Regeneron Pharmaceuticals, Inc. which can be found using ticker (REGN) have now 25 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The range between the high target price and low target price is between $1,230.00 and $800.00 calculating the mean target price we have $1,098.79. Given that the stocks previous close was at $824.48 this would indicate that there is a potential upside of 33.3%. There is a 50 day moving average of $1,021.70 while the 200 day moving average is $1,010.30. The total market capitalization for the company now stands at 91.04B. The price for the stock stands currently at: $828.42 USD
The potential market cap would be $121,323,051,591 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 20.49, revenue per share of $128.69 and a 7.41% return on assets.
Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Its commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases. Its marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, REGEN-COV, Kevzara (sarilumab) Solution for Subcutaneous Injection, Evkeeza (evinacumab) Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. The Company also provides Expresse service assurance and CloudCheck WiFi experience management solutions.
